


Your Hematology Oncology CRO Partner to Navigate Complexity with Confidence

Capabilities across the development continuum to help bring better outcomes for patients

IQVIA is a global leader in hematology and oncology clinical development, offering comprehensive, integrated solutions that span the entire drug development lifecycle. With extensive therapeutic expertise, advanced analytics, and a global footprint, IQVIA helps sponsors navigate the complexities of trials and bring life-changing therapies to patients faster.



Site networks and precision recruitment

Our established relationships with global experts, from academic centers and community oncology networks to nonprofit organizations and advocacy groups, can support studies from first in human novel trial designs to seamless adaptive trials in later phase development. Through access to anonymized patient level data, such as EMR, longitudinal prescriptions, claims, genomic profiles, and biomedical insights, collected directly from oncology specialists, IQVIA enables precision recruitment. This data-driven approach allows identification of both site-based and eligible patients beyond the site's known population, enhancing trial efficiency.

Medical and clinical development expertise

IQVIA offers comprehensive medical and clinical development expertise, led by therapeutic medical experts with direct industry and investigator experience. These specialists guide clinical development and trial strategy through end-to-end solutions, including pre-approval validation, IND/CTA filings, early-phase study design, and dose optimization. For late-phase development, IQVIA integrates real-world evidence to support long-term follow-up, market strategy, and successful product launch.

Specialized delivery and study management

IQVIA offers a specialized delivery and study management approach through dedicated execution

teams from early phase oncology, cell and gene therapies, to radiopharmaceuticals. Our seasoned project leaders collaborate across multi-disciplinary study teams to proactively mitigate risk, enhance patient safety, and drive efficacy to accelerate timelines in complex clinical programs. Additionally, our IQVIA Biotech delivery teams can provide agile, scalable solutions designed for small biotech and biopharma companies, enabling more efficient clinical trial execution.



Regulatory and drug development strategy

We provide strategic insights across all major global regulatory agencies (FDA, CDER, EMA, PMDA, MHRA, NMPA, and TGA) to inform and guide clinical development programs. Our integrated approach enables sponsors to anticipate regulatory shifts and align cross-functional strategies needed for drug development. We help sponsors stay ahead of evolving regulatory landscapes and support successful global submissions.

End-to-end laboratory solutions

IQVIA Laboratories is a global leader in drug discovery and development laboratory services, offering a comprehensive suite of central laboratory and specialty biomarker services. The global laboratory network is equipped with a comprehensive array of validated assays, utilizing the latest technologies in IHC, FISH, molecular diagnostics, NGS, circulating protein markers, and flow cytometry.

Real-world data and studies

IQVIA offers access to non-identified, integrated global real-world data from over 15 million oncology patients across more than 30 primary cancer types, spanning a decade of longitudinal insights. This includes rich EMR and genomics datasets, supported by indication-specific evidence platforms designed to improve value

and outcomes across global healthcare systems. Our technology-enabled solutions provide intuitive, near real-time access to insights, empowering clinical and commercial teams to make informed decisions that accelerate innovation and improve patient care.

Evidence networks

Leverage our robust evidence networks, curated portfolios of high quality data, research ready assets across diverse geographies, and therapeutic areas to generate impactful evidence that informs strategic decision making. Our deep real-world expertise allows sponsors to tap into clinically rich, complex datasets that support advanced analytics and meaningful insights.

Commercial optimization

IQVIA helps improve overall market performance by integrating hematology and oncology expertise with advanced data, analytics, and technology. Our strategic approach enables evidence-based decision making, supporting differentiated product positioning and accelerating time-to-market. By aligning clinical and commercial strategies, we help sponsors maximize value, enhance competitive advantage, and deliver novel therapies to patients faster.



IQVIA as your trusted hematology oncology CRO

IQVIA has a proven track record in successfully delivering hematology and oncology clinical trials. In the last 5 years:



>1,200 solid tumors and hematological malignancies clinical trials with >186,000 patients enrolled in 85+ countries globally



>155 classical hematology clinical trials with >8,200 patients enrolled in 80+ countries globally

84% of FDA-approved oncology drugs and 95% of FDA-approved hematology drugs from 2016-2024 involved IQVIA.

Our therapeutic expertise ensures sponsors are asking the right questions and uncovering new opportunities for innovation. IQVIA's cross-functional teams bring deep knowledge across a wide range of therapeutic areas, helping clients connect the dots, apply best practices, and remain at the forefront of scientific discovery.

IQVIA is redefining hematology and oncology clinical development by shifting from a drug-centered to a patient-centered approach. We leverage patient insights to inform trial design, enhance patient recruitment through digital engagement and decentralized trials, and empower patients with personalized healthcare tools.

Our commitment to innovation, data-driven decision-making, and collaborative partnerships positions IQVIA as the ideal CRO for sponsors aiming to accelerate development timelines, reduce trial risk and complexity, and improve outcomes for patients worldwide.



Talk to us. We'll help you navigate complexity with confidence.